- Home
- TDF vs ABEO Comparison
TDF vs ABEO Comparison
Compare TDF & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TDF | ABEO |
|---|---|---|
| Founded | 1994 | 1974 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.0M | 280.2M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | TDF | ABEO |
|---|---|---|
| Price | $10.88 | $4.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $18.75 |
| AVG Volume (30 Days) | 90.9K | ★ 1.2M |
| Earning Date | 01-01-0001 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | N/A | ★ 1.01 |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $1,864.43 |
| Revenue Next Year | N/A | $82.04 |
| P/E Ratio | ★ N/A | $4.49 |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $8.13 | $3.93 |
| 52 Week High | $12.20 | $7.54 |
Technical Indicators
Market Signals| Indicator | TDF | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 31.77 | 36.90 |
| Support Level | $10.17 | $4.53 |
| Resistance Level | $11.42 | $5.62 |
| Average True Range (ATR) | 0.24 | 0.21 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 37.00 | 22.22 |
Price Performance
Historical ComparisonAbout TDF Templeton Dragon Fund Inc.
Templeton Dragon Fund Inc is a closed-end management investment company. The fund seeks long-term capital appreciation by investing majority of its total assets in equity securities of China companies. It invests in various sectors such as gas & consumable fuels, auto components, banks, beverages, communications equipment, healthcare equipment & supplies, restaurants & leisure, household durables and many others.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.